May2026– 4basebio plc (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation ...

The deal is Lilly's seventh acquisition of 2026 and centers on Engage's non-viral DNA delivery platform, Tethosome ...

Oncology focused biotech to utilise 4basebio’s opDNA® technology to support Phase II clinical trial of immunotherapy candidate Multi-year, ...

Transaction terms include an undisclosed upfront cash payment plus development milestones, for up to $202 million total consideration, with no additional financial details disclosed. Engage’s ...

Engage Bio’s Tethosome platform is designed to improve the potency, tolerability, and redosability of non-viral DNAAcquisition combines Engage’s innovative platform with Lilly’s broad genetic ...

RNA is the means of translating the genetic code embedded in DNA into proteins, which serve as enzymes, transporters, ...

The video argues that cancer is not one disease but hundreds, which is why curing it has been so difficult. It focuses on the ...

The CEO of Caszyme, a biotech company in Vilnius, Lithuania, presented details of Cas12l, a novel compact Cas nuclease with a ...

Vaccines are in the news a lot these days due to the hantavirus outbreak. There’s so much misinformation about vaccines that one article wouldn’t be enough to counter all the ridiculous claims, from ...

Earlier this month, a cluster of severe acute respiratory illnesses aboard the Dutch-flagged cruise ship MV Hondius was reported to the World Health Organization (WHO). The infections have since been ...

Combining pre-formed vesicles with nucleic acid cargo at the point of care can remove long-standing barriers to personalized ...